Condition
Carcinoma, Non-small-cell Lung
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 21 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
21 shownA Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in ArgentinaNCT03321695 · 2017-12-27
COMPLETEDA Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid TumorsNCT03261947 · 2017-10-25
COMPLETEDStudy of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)NCT02758587 · 2017-07-04
UNKNOWNThe Watch the Spot TrialNCT02623712 · 2017-03-06
COMPLETEDIsolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung CancerNCT02410603 · 2016-12-01
COMPLETEDA Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ SystemNCT02370303 · 2014-08-01
COMPLETEDPemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction ChemotherapyNCT02004184 · 2013-12-01
TERMINATEDA Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung CancerNCT00983307 · 2009-08-27
COMPLETEDA Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)NCT00654420 · 2008-03-19
COMPLETEDImmune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)NCT00406302 · 2007-01-01
COMPLETEDPrevention of Radiation Pneumonitis After Three-dimensional Conformal Radiation Therapy (3D-CRT) in Patients With Non-small-cell Lung CancerNCT00349102 · 2006-07-01
COMPLETEDRandomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)NCT00312975 · 2006-05-01
COMPLETEDStudy of Tarceva and Targretin in Stage I-II Lung CancerNCT00125372 · 2005-12-01
COMPLETEDStudy of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung CancerNCT00125359 · 2005-08-01
COMPLETEDEMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given CyclophosphamideNCT00132522 · 2005-05-01
COMPLETEDStudy of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)NCT00050336 · 2002-12-01
TERMINATEDPhase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung CancerNCT00047801 · 2002-10-01
COMPLETEDPhase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung CancerNCT00040638 · 2002-07-01
COMPLETEDOSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerNCT00036647 · 2001-11-01
COMPLETEDA Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung CancerNCT00153842 · 2001-08-01
TERMINATEDA Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based ChemotherapyNCT00035516 · 2001-02-01
COMPLETEDCommon interventions
ErlotinibDRUG2best supportive careDRUG1Bexarotene (targretin)DRUG1Breath holdingRADIATION1cetuximabDRUG1CP-675,206DRUG1DalotuzumabDRUG1DefactinibDRUG1DocetaxelDRUG1EMD 273066DRUG1EpothiloneDRUG1erlotinib (Tarceva) and bexarotene (Targretin)DRUG1erlotinib and bexaroteneDRUG1Free breathingRADIATION1Hypofractionated RadiotherapyRADIATION1Less Frequent Surveillance StrategyOTHER1Lonafarnib (SARASAR)DRUG1maintenance pemetrexedDRUG1More Frequent Surveillance StrategyOTHER1oxaliplatinDRUG1PembrolizumabDRUG1pemetrexed at progressionDRUG1surgeryPROCEDURE1TAK-931DRUG1Tarceva (erlotinib HCl, OSI-774 )DRUG1
Leading sponsors
Dartmouth-Hitchcock Medical Center
2
Mayo Clinic
2
Merck Sharp & Dohme LLC
2
Telik
2
AstraZeneca
1
Centre Leon Berard
1
EMD Serono
1
Hoffmann-La Roche
1
Kaiser Permanente
1
Konstantin Dragnev
1
Millennium Pharmaceuticals, Inc.
1
NHS Greater Glasgow and Clyde
1
Norwegian University of Science and Technology
1
OSI Pharmaceuticals
1
R-Pharm
1
Trial status mix
COMPLETED17
TERMINATED3
UNKNOWN1
Phase mix
PHASE211
PHASE14
PHASE34
NA2
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.